KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Long-Term Debt Repayments (2019 - 2023)

Historic Long-Term Debt Repayments for Aquestive Therapeutics (AQST) over the last 3 years, with Q1 2023 value amounting to $9.1 million.

  • Aquestive Therapeutics' Long-Term Debt Repayments changed N/A to $9.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $31.6 million, marking a year-over-year increase of 4038.22%. This contributed to the annual value of $23000.0 for FY2024, which is 9995.54% down from last year.
  • According to the latest figures from Q1 2023, Aquestive Therapeutics' Long-Term Debt Repayments is $9.1 million.
  • In the past 5 years, Aquestive Therapeutics' Long-Term Debt Repayments registered a high of $49.4 million during Q3 2019, and its lowest value of $9.1 million during Q1 2023.
  • Over the past 3 years, Aquestive Therapeutics' median Long-Term Debt Repayments value was $22.5 million (recorded in 2020), while the average stood at $27.0 million.